Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319177 | 0.86 | SOS1 (0.37) | DPP4DPP7CNR1CNR2GPR139 | |
| SCHEMBL3319712 | 0.84 | CNR1 (0.44) | CNR1CNR2OPRL1 | |
| SCHEMBL23212018 | 0.79 | DPP4 (0.45) | DPP4DPP7CNR1CNR2P2RX7 | |
| SCHEMBL3315968 | 0.78 | ADRB2 (0.48) | DPP4DPP7RAB9A | |
| SCHEMBL3314490 | 0.78 | DPP4 (0.44) | DPP4DPP7CNR1CNR2MDM2 | |
| SCHEMBL3317620 | 0.77 | ADRB2 (0.41) | DPP4DPP7CNR1CNR2P2RX7 | |
| SCHEMBL3314526 | 0.75 | CACNA2D1 (0.43) | GPR139HPGDRAB9A | |
| SCHEMBL21723003 | 0.74 | HPGD (0.70) | P2RX7HPGDRAB9A | |
| SCHEMBL3318607 | 0.73 | DPP4 (0.48) | DPP4DPP7CNR1CNR2MDM2 | |
| SCHEMBL30202666 | 0.72 | GPR139 (0.48) | P2RX7GPR139MDM2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | DPP4 4101/4885DPP7 4127/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.